PROTA THERAPEUTICS
Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel combination probiotic allergen oral immunotherapy treatments. Prota holds an exclusive license to the patented probiotic food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures' Healthcare Fund III) – including $5M from the Austral... ian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance their clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT100 peanut allergy treatment.
PROTA THERAPEUTICS
Social Links:
Industry:
Biotechnology Product Research Therapeutics
Founded:
2016-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.protatherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Mobile Non Scaleable Content Microsoft Exchange Online Amazon
Current Employees Featured
Founder
Investors List
OneVentures
OneVentures investment in Series A - Prota Therapeutics
Official Site Inspections
http://www.protatherapeutics.com Semrush global rank: 5.74 M Semrush visits lastest month: 1.46 K
- Host name: web2.brightspire.com.au
- IP address: 95.111.217.214
- Location: Ukraine
- Latitude: 50.4522
- Longitude: 30.5287
- Timezone: Europe/Kiev
More informations about "Prota Therapeutics"
Company Background - Prota Therapeutics
Company Background. Established in 2016, Prota Therapeutics is an Australian biotech company dedicated to developing and commercializing cutting-edge oral immunotherapy treatments.See details»
Prota Therapeutics - Crunchbase Company Profile
Organization. Prota Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Prota Therapeutics is a developer of new treatment for peanut allergy in …See details»
Management | Prota Therapeutics
Prof. Mimi Tang. Chief Executive Officer. Scientific Founder. Clinician researcher, recognized as a global thought leader in allergy, over 330 scientific publications, 25+ years’ experience as a …See details»
Prota Therapeutics US $21 Million Financing Led by SPRIM Global …
Jan 16, 2024 Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trial MELBOURNE, AUSTRALIA / ACCESSWIRE / January …See details»
Prota Therapeutics raises $31m for peanut allergy cure
Jan 18, 2024 Prota Therapeutics is using high doses of peanut protein in its unique method of therapy to treat peanut allergies . Tang, who was elevated to CEO of Prota Therapeutics in 2020, described the company’s remission …See details»
Prota Therapeutics Achieves 51 Percent Peanut Allergy ... - BioSpace
May 16, 2022 Children’s ability to eat peanut freely and safely delivers meaningful improvement in quality of life for families and patients. MELBOURNE, Australia, May 16, 2022 …See details»
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone ...
Feb 9, 2022 The randomized controlled trial was designed to analyze the effect of an oral immunotherapy (the gradual introduction of the allergenic food) delivered via a proprietary, …See details»
Prota Therapeutics Pty Ltd Secures $32M in Series A Funding for ...
Prota Therapeutics Pty Ltd, an innovative Australian biotech company founded in 2016, is thrilled to announce that it has successfully raised AUD $32 million in its latest funding round. This …See details»
Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission …
May 16, 2022 Children's ability to eat peanut freely and safely delivers meaningful improvement in quality of life for families and patients. MELBOURNE, Australia, May 16, 2022 …See details»
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone ...
Feb 9, 2022 The paediatric peanut allergy market is estimated to be worth $3 billion by 2027, with around 1.1 million patients between the ages of 1-17 diagnosed in the US alone last …See details»
Prota Therapeutics US $21 Million Financing Led by SPRIM Global ...
Jan 16, 2024 Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trial. MELBOURNE, AUSTRALIA / ACCESSWIRE / January …See details»
Board of Directors | Prota Therapeutics
Patrick Machado. Independent Director and Chair. 30 years’ experience in the biotech sector and a deep understanding of the scientific and regulatory processes involved in bringing new …See details»
Prota Therapeutics - PitchBook
Prota Therapeutics General Information Description. Developer of immunotherapy-based treatment designed to help treat peanut allergy in children. The company's treatment offers a …See details»
Prota Therapeutics Announces Publication in Allergy of Long-Term …
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for …See details»
Allergies biotech startup Prota Therapeutics innoculated with $32 ...
Jan 17, 2024 Melbourne biotech startup Prota Therapeutics has raised US$21 million (A$32m) ahead of a Phase 3 clinical trial for its oral therapy treatment for peanut allergy.See details»
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone ...
Feb 9, 2022 Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health; Data shows that 51% of participants achieved sustained unresponsiveness …See details»
Australia’s ProTA accelerates the development of immunotherapy …
Allergy immunotherapy company ProTA Therapeutics Pty Ltd (ProTA) will accelerate the development of a possible treatment for life-threatening peanut allergy with the appointment of …See details»
Prota Therapeutics - Craft
Prota Therapeutics is a biotech company developing the treatment for food allergies. It offers a combination probiotic peanut oral immunotherapy (PRT100) that targets peanut allergy.See details»
Media - Prota Therapeutics
Melbourne, Australia: Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce results from a follow up study of the probiotic and peanut immunotherapy …See details»